Effects of Targeted Amino Acid Supplementation for People With Parkinson's Disease on Amino Acid Profiles and Health Related Markers

Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this clinical trial is to learn if a tailored amino acid supplement works to help adults living with Parkinson's disease to improve nutrition, metabolic function, body composition, and physical and mental function. The main questions it aims to answer are: Does the tailored amino acid supplement increase essential amino acids (nutritional status)? Does the tailored amino acid supplement increase an antioxidant (complex amino acid) and decrease an amino acid associated with oxidative stress? Does the tailored amino acid supplement improve physical and mental health compared to a placebo supplement? Researchers will compare the tailored amino acid supplement to a placebo (a look-alike substance that contains no active ingredients) to see if the tailored amino acid supplements work to support health for people with Parkinson's disease. Participants will: Take the tailored amino acid supplement or a placebo every day for 6 months, visit the lab at baseline, after 3 months, and after 6 months for fasting blood draws, body composition assessment, and physical and mental health testing and keep a diary of their food intake and supplement intake.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 60
Maximum Age: 80
Healthy Volunteers: f
View:

• Male and Females.

• 60-80 Years.

• Previous diagnosis of idiopathic Parkinson's Disease by patient report.

• Use of dopamine replacement medication (e.g. levodopa) for at least 2 years.

• On a stable dose of dopamine replacement medication for at least 3 months with no plans for change in the next two months.

Locations
United States
Connecticut
University of Connecticut
RECRUITING
Storrs
Contact Information
Primary
Carlos Rehbein, MS
carlos.rehbein@uconn.edu
860-486-1121
Time Frame
Start Date: 2025-10-31
Estimated Completion Date: 2027-11
Participants
Target number of participants: 30
Treatments
Placebo_comparator: Control
The inert amino acid (alanine) will serve as an isonitrogenous control.
Experimental: Targeted Amino Acid Supplement
Blend of the essential amino acids (Leucine \& Tryptophan), a conditionally essential amino acids (Arginine \& Taurine), and non-essential amino acids (Glutamate \& Tyrosine) designed to meet the unique nutritional needs of people with Parkinson's disease (PD).
Related Therapeutic Areas
Sponsors
Collaborators: United States Department of Agriculture (USDA)
Leads: Cristina Colon-Semenza

This content was sourced from clinicaltrials.gov